ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

2:00PM-2:15PM
Abstract Number: 1666
Treatment with Rilzabrutinib was associated with Rapid and Sustained Reduction in Disease Activity in Patients with IgG4-RD Previously Treated or Naïve to B cell Depletion
Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II: Models and Mechanisms (1662–1667)
2:15PM-2:30PM
Abstract Number: 1655
Aberrant Noncoding RNAs Are Enriched in Extracellular Vesicles and Implicated in Interferon Activation
Abstracts: Cytokines & Cell Trafficking (1650–1655)
2:15PM-2:30PM
Abstract Number: 1661
Artificial Intelligence applied to Patient Reported Outcomes and Passive Physiologic Sensor Data can Accurately Classify Low Disease Activity in Rheumatoid Arthritis Patients
Abstracts: Health Services Research (1656–1661)
2:15PM-2:30PM
Abstract Number: 1679
Does First-Line b- or tsDMARDs Choice Influence Progression to Difficult-to-Treat Rhumatoid arthritis? Insights from our longitudinal RA UCLouvain Brussels cohort
Abstracts: Rheumatoid Arthritis – Treatment I: Preventative and Novel Treatments (1674–1679)
2:15PM-2:30PM
Abstract Number: 1673
Is Transient Synovitis of the Hip preclinical Juvenile SpA ? A follow-up study
Abstracts: Pediatric Rheumatology – Clinical I (1668–1673)
2:15PM-2:30PM
Abstract Number: 1667
Recurrent or Incident Pericarditis With Concurrent Autoimmune Disease: Stable Control With Rilonacept Interleukin-1 Pathway Inhibition
Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II: Models and Mechanisms (1662–1667)
2:15PM-2:30PM
Abstract Number: 1685
The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease
Abstracts: Sjögren’s Disease – Basic & Clinical Science (1680–1685)
3:00PM-3:15PM
Abstract Number: 1710
Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level
Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Advances in Psoriatic Disease (1710–1715)
3:00PM-3:15PM
Abstract Number: 1704
Relationships between Neighborhood Disadvantage, Cumulative Social Disadvantage, and JIA Outcomes: A CARRA Registry Study
Abstracts: Healthcare Disparities in Rheumatology (1704–1709)
3:00PM-3:15PM
Abstract Number: 1692
Rheumatoid factor is associated with increased gut permeability and migration of B cells to the joint via CXCR3 in rheumatoid arthritis
Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1691–1697)
3:00PM-3:15PM
Abstract Number: 1716
The frequency and impact of cardiovascular disease in systemic lupus erythematosus: a Nationwide, matched case-control study.
Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes II: Morbidity & Mortality (1716–1721)
3:00PM-3:15PM
Abstract Number: 1686
The Prevalence of Depressive Symptoms and Persistent Depression among Older Adults with Systemic Lupus Erythematosus (SLE)
Abstracts: ARP I: Multidimensional Influences on Health in SLE (1686–1691)
3:00PM-3:15PM
Abstract Number: 1698
X Chromosome DNA Methylation Changes Suggest Epigenetic Contributions to Immune Dysregulation in Male Lupus
Abstracts: Genetics, Genomics & Proteomics (1698–1703)
3:15PM-3:30PM
Abstract Number: 1705
Associations Between Social Risk Factors and Acute Care Use Among Patients with Rheumatic Conditions
Abstracts: Healthcare Disparities in Rheumatology (1704–1709)
3:15PM-3:30PM
Abstract Number: 1687
Body Esteem and Sexual Function in Women with Systemic Lupus Erythematosus
Abstracts: ARP I: Multidimensional Influences on Health in SLE (1686–1691)
  • «Previous Page
  • 1
  • …
  • 54
  • 55
  • 56
  • 57
  • 58
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology